SEATTLE, Aug. 3, 2011 /PRNewswire via COMTEX/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the following two conferences:

2011 Canaccord Genuity Growth Conference
August 10, 2011
9:00 a.m. EDT
Boston, MA

Wedbush 2011 Life Sciences Management Access Conference
August 17, 2011
8:35 a.m. EDT
New York, NY

The presentations will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at http://www.omeros.com/.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

SOURCE Omeros Corporation